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Abstract: Tobacco smoking remains the single most preventable cause of morbidity and mortality in developed countries and poses 
a significant threat across developing countries where tobacco use prevalence is increasing. Nicotine dependence is a chronic disease 
often requiring multiple attempts to quit; repeated interventions with pharmacotherapeutic aids have become more popular as part of 
cessation therapies. First-line medications of known efficacy in the general population include varenicline tartrate, bupropion hydro-
chloride, nicotine replacement therapy products, or a combination thereof. However, less is known about the use of these products in 
marginalized groups such as the indigenous, those with mental illnesses, youth, and pregnant or breastfeeding women. Despite the effi-
cacy and safety of these first line pharmacotherapies, many smokers continue to relapse and alternative pharmacotherapies and cessation 
options are required. Thus, the aim of this review is to summarize the existing and developing pharmacotherapeutic and other options for 
smoking cessation, to identify gaps in current clinical practice, and to provide recommendations for future evaluations and research.
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Tobacco Use
Since the 1950s, we have observed significant 
reductions in tobacco use prevalence across many 
countries.1–4 Despite these reductions, tobacco smok-
ing remains the single most preventable cause of 
morbidity and mortality, contributing to more drug-
related hospitalizations and deaths than alcohol and 
illicit drug use combined.1 Every year, approxi-
mately 5.4 million people die from tobacco-related 
diseases, translating to 1 in every 10 deaths among 
adults  worldwide.5 Tobacco use is known to cause up 
to 90% of all lung cancers and is a major risk factor 
of coronary heart disease, stroke, peripheral vascular 
disease, chronic obstructive pulmonary disease, repro-
ductive and fetal developmental diseases, and many 
other conditions.1,6 Tobacco cessation, even after a 
short period of time, is known to produce significant 
health benefits within as little as 20 minutes. Within 
12 weeks of smoking cessation, improvements in oxy-
gen transportation, smell, taste, breathing, energy, and 
immune responses are observed. Within 12 months, 
the risk of coronary heart disease will return to half 
that of a current smoker and is reduced to that of a 
non-smoker by 15 years.7  Moreover, smoking cessa-
tion treatments have greater cost effectiveness and 
clinical efficacy in comparison to other preventative 
health measures such as treatment of hypertension 
and hypercholesterolemia,8–10 and research has shown 
that the cost per life year saved by smoking cessation 
interventions makes it one of the most cost-effective 
health care interventions.10,11
For these reasons, assisting individuals to stop 
smoking is a key health improvement objective in 
many countries12–14 and pharmacotherapeutic options 
are increasingly being considered, particularly for indi-
viduals with high levels of nicotine addiction. Current 
first-line pharmacotherapies include nicotine replace-
ment therapy, bupropion hydrochloride, and vareni-
cline tartrate, with research suggesting that combining 
these with behavioral counseling increases efficacy 
and helps smokers achieve long term  abstinence.15 
Yet, these medications show some limitations and sig-
nificant resources are invested into the development 
of designer smoking cessation pharmacotherapies, 
which target specific pathophysiological mechanisms 
in nicotine addiction in an attempt to improve the 
effectiveness and safety of  pharmacotherapeutic ces-
sation aids. In addition, adaptation of medications 
used primarily to treat other conditions which have 
the potential to act as smoking cessation aids are also 
being evaluated,16 as are novel adaptations to exist-
ing smoking cessation treatments.17–19 As such, this 
 article is intended to provide the reader with an over-
view of current and emerging pharmacotherapeutic 
options for smoking cessation and provides recom-
mendations for clinical practice, future evaluations, 
and research.
current pharmacotherapeutic  
Options for smoking cessation
The choice of any pharmacotherapy for smoking 
cessation should be guided by an individual’s pref-
erence, contraindications, and precautions for use.13 
 Consideration should be given to specific factors 
such as the potential for adverse events, possible drug 
interactions, the individual’s experience with pharma-
cotherapy, convenience, availability, and cost before 
prescribing any pharmacological interventions to aid 
smoking cessation.10 The level of nicotine addiction 
the individual is reported to have should also be taken 
into account based on a validated scale such as the 
Fagerström test for nicotine dependence.20 Smoking 
cessation guidelines and treatment algorithms recom-
mend the use of pharmacotherapy only in the pres-
ence of nicotine addiction to increase chances of a 
successful quit attempt, while non-pharmacological 
support is recommended for smokers who are not 
nicotine-dependent and those unwilling or unable 
to use pharmacotherapy.10,13,14,21 A systematic search 
of the Cochrane Database of Systematic Reviews’ 
Tobacco Addiction Group register was conducted to 
identify current and emerging pharmacotherapeutic 
options for smoking cessation. In addition, a search 
of Medline, EMBASE, and online clinical trial regis-
tries were also conducted with the key words smoking 
OR tobacco OR nicotine OR tobacco cessation OR 
smoking cessation AND pharmacotherap*. First-line 
pharmacotherapies have been listed in ranked order 
of efficacy.
First-line therapies
Varenicline tartrate (Chantix or Champix) is a nico-
tinic receptor partial agonist designed to selectively 
activate the α4β2 nicotinic acetylcholine  receptor. 
It blocks the effect of subsequent nicotine challenge 
on mesolimbic neuronal dopamine release, while 
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 mimicking the action of nicotine, causing the release 
of mesolimbic dopamine.22 Clinical practice guidelines 
report that varenicline is the most effective form of sin-
gle pharmacotherapy for smoking cessation based on 
available evidence.10 A Cochrane meta-analysis of 14 
trials comparing varenicline to placebo with respect to 
quit rate produced a risk ratio of 2.27 (95% CI 2.02 to 
2.55), and compared to pharmacologically unassessed 
quit attempts varenicline improved the chances of 
long-term abstinence by two- to  three-fold.23 Statisti-
cally significant improvements have also been shown 
with varenicline for patients admitted to the hospital 
with smoking-related illnesses at 12 months follow-
up.24 Varenicline is reported to be a superior smoking 
cessation aid to date for long-term abstinence in the 
general population, with direct and indirect compari-
sons with bupropion,100 nicotine replacement therapy 
products,86 and cytisine.101 The most common adverse 
event is nausea, which is reported to be mild, self-
limiting, and resolving over time (RR 3.28; 95% CI 
2.89 to 3.73). Further details pertaining to dosing and 
prescription, efficacy, and adverse events are reported 
in Table 1.
Bupropion hydrochloride (Zyban SR or Wellbutrin 
SR) is a norepinephrine and dopamine re- uptake 
inhibitor that decreases nicotine cravings and symp-
toms of withdrawal26 while also interacting with neural 
pathways underlying nicotine addiction.25 It can also 
be used as an antidepressant and is thought to reduce 
the depressive symptoms of nicotine withdrawal, as 
nicotine itself may cause antidepressant effects that 
bupropion helps maintain.26 Evidence from clinical 
trials report that bupropion aids long-term smoking 
abstinence when compared to placebo and nicotine 
replacement therapy products; however, when com-
pared to varenicline, it showed reduced quitting suc-
cess.23,25,27 The most common adverse events include 
insomnia, dry mouth, and nausea.25 Further details 
pertaining to dosing and prescription, efficacy, and 
adverse events are reported in Table 2.
Nicotine replacement therapy (NRT) products are 
designed to control cravings by replacing nicotine 
through various delivery systems. Nicotine patches 
differ from other NRT products (eg, lozenges and 
gum) in that they deliver nicotine slowly and pas-
sively over time.28 Transdermal patches are available 
in doses varying from 5 mg to 22 mg over a 16- to 
24-hour period. Lozenges and chewing gum are 
available in strengths of 2 mg or 4 mg; however, no 
available NRT products deliver nicotine as quickly as 
a cigarette, being between 1 mg and 3 mg of nicotine 
per cigarette with the typical pack-per-day smoker 
absorbing 20 to 40 mg of nicotine per day.28,29 The 
most recent product on the market is the nicotine 
quick mist, which is a 1-mg oral mouth spray that 
produces levels of plasma nicotine similar to nicotine 
gums and lozenges.30 A review of 132 trials found that 
NRT patches improved the likelihood of successful 
smoking cessation by 50% to 70% regardless of the 
setting.28 NRT products are available over the counter 
and the major side effects vary depending on the type 
of product, but typically include skin irritation from 
patches and irritation to the inside of the mouth from 
gum and tablets.28 Further details pertaining to dos-
ing and prescription, efficacy, and adverse events are 
reported in Table 1.
Other pharmacotherapeutic treatment 
options for smoking cessation
Nicotine receptor antagonists
Nicotine receptor antagonists include varenicline 
tartrate (as reported above), cytisine, dianicline, 
and mecamylamine, all of which moderate levels of 
dopamine to counteract withdrawal symptoms (ago-
nist) and reduce smoking satisfaction (antagonist).23 
A detailed summary of varenicline is described above 
and cytisine shows the highest efficacy of the remain-
ing nicotine receptor agonists. A review of nicotine 
agonists identified one trial examining dianicline as 
a smoking cessation therapy, which was found to be 
ineffective.23 A separate Cochrane review examining 
mecamylamine identified two studies for inclusion, 
the results off which suggested that a combination 
of nicotine replacement therapy and mecamylam-
ine may be superior to nicotine replacement therapy 
alone.31 However, these results were based on two 
studies with small sample sizes, and confirmation in 
larger studies is required before the treatment can be 
recommended clinically.31
Cytisine (Tabex) is derived from the plant Cytisus 
laburnum and acts as a low-efficacy partial nicotine 
agonist binding to subtypes of neuronal nicotine 
receptors, particularly the α4β2 subunits. Recent 
 studies have highlighted the potential for this drug to 
be used in low- to medium-income countries27,33 where 
tobacco cessation is not supported by  insurance plans 
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or the national health service23 as well as in the indig-
enous setting.34 Efficacy trials show modest improve-
ments in quit rates with outcomes similar to studies 
using nicotine replacement therapy,23 though twice 
as effective as placebo.34 Further details pertaining to 
dosing and prescription, efficacy, and adverse events 
are reported in Table 2.
Pharmacological therapies that are used primarily 
to treat other medical conditions may also be used for 
treating nicotine addiction. As research aimed at explor-
ing and understanding the biological mechanisms of 
nicotine addiction develop, new opportunities are aris-
ing for existing pharmacological agents to be translated 
into the tobacco arena. The following section provides 
a summary of such medications, which have potential 
applications in treating nicotine addiction.
Anxiolytics
Anxiolytics are proposed as a smoking cessation 
treatment because of their ability to abate anxiety, one 
of the common symptoms of smoking  cessation.35 
There are many types of anxiolytics that may have a 
role as smoking cessation treatments including clo-
nidine, buspirone, diazepam, doxepin, meprobam-
ate, ondansetron, and the beta-blockers metoprolol, 
oxprenolol, and propanolol.35 The anxiolytic cloni-
dine has the most evidence evaluating efficacy for 
smoking cessation out of the nine anxiolytics, and as 
such are a more detailed description of clonidine is 
reported below and in Table 2.
Clonidine is marketed as an antihypertensive but 
also has applications for drug and alcohol withdrawal 
symptoms,36,37 as a treatment for chronic pain,38 
menopausal flushes39,40 and Tourette’s syndrome. In 
a systematic review of tobacco withdrawal symptom 
studies, clonidine has been reported to ameliorate 
cravings, anxiety, restlessness, tension, and hunger, 
but also caused some side effects such as sedation, 
dry mouth, and dizziness, with twice as many patients 
taking clonidine discontinuing medication compared 
to placebo.42 For these reasons, clonidine is not con-
sidered a first-line treatment; however it may be ben-
eficial for targeted populations such as smokers who 
are likely to experience high levels of anxiety and 
agitation when stopping smoking and subsequently 
may benefit from the sedative effects.42 Further details 
pertaining to dosing and prescription, efficacy, and 
adverse events are reported in Table 2.
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Other antidepressants
Other antidepressants, including tricyclics (doxepin, 
imipramine, and nortriptyline), monoamine oxidase 
inhibitors (moclobemide and selegiline), selective 
serotonin reuptake inhibitors (fluoxetine, paroxetine, 
and sertraline), atypical antidepressants (bupropion—
mentioned above, tryptophan, and venlafaxine), and 
extracts (St. John’s Wort—Hypericum perforatum L.) 
have also been examined as smoking cessation aids.25 
A Cochrane review of antidepressants for smoking 
cessation identified 66 trials, 49 or which were inves-
tigating bupropion and 9 nortriptyline.25 Pooling of 
bupropion and nortriptyline studies indicated long-
term smoking cessation efficacy similar to that of 
nicotine replacement therapies, while selective sero-
tonin reuptake inhibitors did not.25 As bupropion is 
discussed above as a first-line smoking cessation aid, 
a detailed summary of nortriptyline is reported below 
and in Table 2 as it shows the most evidence of the 
remaining antidepressants for use as a smoking ces-
sation medication.
Opioid antagonists
Opioid antagonists including naltrexone, buprenor-
phine, and naloxone are thought to be potentially 
effective smoking cessation medications as they 
have the potential to attenuate the rewarding effects 
of cigarette smoking.43 Smokers report both positive 
and negative effects associated with smoking with 
the reinforcing properties of nicotine theorized to be 
mediated through the release of various neurotrans-
mitters in the brain. There is evidence to suggest that 
the endogenous opioid system may have a reinforcing 
role in smoking, while other studies report that the 
system may also have a mediating role with nicotine 
withdrawal.43
Naltrexone is a long-acting opioid agonist mar-
keted as a drug that blunts certain effects of narcotics 
such as heroin, meperidine, morphine, and ocycodone 
and is also used in the treatment of alcoholism.43 
 Naltrexone is thought to reduce nicotine cravings by 
diminishing the activation of mesolimbic dopamine 
receptors; thus, combination therapy with NRT is 
thought to offer an additive effect for achieving 
smoking abstinence due to its different mechanisms 
of action.43 Further details pertaining to dosing and 
prescription, efficacy, and adverse events are reported 
in Table 2.
Cannabinoid type 1 receptor antagonists
Cannabinoid type 1 receptor antagonists such as 
rimonabant and taranabant are thought to assist smok-
ing cessation by restoring the balance of the endo-
cannabinoid system, which can be disrupted with 
prolonged exposure to nicotine. Central cannabinoid 
receptors have been implicated in brain reward func-
tion and are thought to play a role in dependence and 
habituation.44 It is thought that rimonabant may work 
by blocking the central cannabinoid receptors thus 
restoring the balance and inhibiting nicotine and food 
cravings.44
Rimonabant was originally manufactured to treat 
obesity and was later proposed as a smoking cessa-
tion aid due to its potential for protecting successful 
quitters from significant post-cessation weight gain. 
Smoking cessation itself is associated with weight 
gain, which deters some smokers from making quit 
attempts; it was hoped that rimonabant would act as a 
cessation aid for these smokers. Reports of increased 
levels of suicidal thoughts and depression resulted in 
withdrawal of rimonabant as a prescription drug in 
European Countries in 2008.44 Further details pertain-
ing to dosing and prescription, efficacy, and adverse 
events are reported in Table 2.
Lobelia
Lobelia (lobeline) is derived from the Indian tobacco 
plant Lobelia inflate and was first synthesized in the 
early 1900s when it was classified as a partial nico-
tinic agonist.45 The first documented use of lobeline as 
a smoking cessation treatment was in the 1930s with 
a variety of dosages and delivery mechanisms tested 
since then, including tablet (8 mg as lobeline sul-
phate), parenteral injection, buffered tablets, and fla-
vored pastilles.46 All of these formulations produced 
varying degrees of adverse effects including gastric 
side effects, dizziness, nausea, vomiting, and throat 
irritation.47,48 In 1993, the FDA announced a ban on 
all over the counter smoking cessation products in the 
United States due to a lack of efficacy data.49 Further 
details pertaining to dosing and prescription, efficacy, 
and adverse events are reported in Table 2.
Silver acetate
Silver acetate is designed to act as an aversive stimulus 
to inspire smoking cessation by producing an unpleas-
ant metallic taste when combined with  cigarettes.50 
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Smokers are encouraged to use silver acetate prod-
ucts such as lozenges, gums, and sprays so that the 
act of smoking becomes unpleasant to diminish or 
stop the urge to smoke.50 Efficacy studies have shown 
a possible small effect of silver acetate, though any 
benefit observed is less than that produced by nico-
tine replacement therapy (NRT) and therefore silver 
acetate is not widely used to promote smoking ces-
sation in the clinical setting with the exception of a 
possible combination use with NRT.50 Further details 
pertaining to dosing and prescription, efficacy, and 
adverse events are reported in Table 2.
Nicobrevin
Nicobrevin has been marketed as a smoking cessation 
aid in 11 countries including the United Kingdom 
(UK), New Zealand, and Germany, though in 2011 a 
governmental review found Nicobrevin to be ineffec-
tive as a smoking cessation aid and identified several 
side effects. Thus, the risks of the product outweighed 
the benefits.51 This resulted in withdrawal of the prod-
uct from the UK and other markets. Nicobrevin is a 
proprietary product containing four active ingredi-
ents, including quinine (15 mg, thought to reduce 
cravings), menthyl valerate (100 mg, acts as a seda-
tive), camphor (10 mg, relieves respiratory congestion 
and gastrointestinal disturbances), and eucalyptus oil 
(10 mg, relieves respiratory congestion and gastro-
intestinal disturbances).52 Further details regarding to 
dosing and prescription, efficacy, and adverse events 
are reported in Table 2.
Adaptive and novel approaches
New formulations and innovative delivery systems 
for existing products are in development53,54 such 
as a straw containing nicotine beads, which allows 
the smoker to place drops of nicotine directly into a 
beverage,19 though safety and efficacy data remains 
unknown. Galenic formulations of varenicline 
are also being developed, including a controlled 
release formulation (ClinicalTrials.gov Identifier: 
NCT00741884 and NCT005227150), a free base 
solution (NCT00774605), and a free base patch 
(NCT01234142, NCT01013454, NCT00774605). 
 Tailoring dosages of existing medications such as 
varenicline and nicotine patches are also being evalu-
ated with administration of up to 5 mg dosages per 
day of varenicline for smokers not experiencing any 
adverse events during the standard first week of titra-
tion (NCT01206010) and 42 mg patches for fast metab-
olizers of nicotine (NCT00956943).  Combinations of 
existing products are also being explored as options 
for enhancing abstinence rates, with some evidence 
of success for combining varenicline with nicotine 
replacement therapy55 (NCT01184664) and bupro-
pion56 (NCT00935818).
Electronic nicotine delivery systems or 
‘E- cigarettes’ are becoming increasingly  popular, 
 particularly among the youth and adolescents as 
 flavored varieties are now being introduced.18 These 
small cigarette-shaped electronic devices use a 
battery-powered heating element, across which a 
solution of nicotine and propylene glycol (though 
other solutions are also used) is drawn. This causes the 
humectant to vaporize and subsequently be inhaled 
via a small tube as a mist.17 Despite marketing of the 
product as a safe alternative to cigarette smoking as 
it does not contain the harmful ingredients normally 
found in cigarettes, there are concerns regarding the 
wide-spread use of these devices, with FDA reports 
of some tested samples containing toxic substances 
including nitrosamines and even diethylene glycol.18 
Moreover, many manufacturers still evade govern-
ment regulation, raising issues around safety and 
harm reduction.17,18 E-cigarettes are currently being 
trialed for smoking cessation and reduction in smok-
ers who are unwilling to quit (NCT01195597).
Immunotherapy, also referred to as nicotine vac-
cines, are currently being developed and evaluated 
through pharmaceutical studies some of which are 
phase III trials, with the most advanced vaccines 
expected to be launched in the first years of the 
2010 decade.54,57 Nicotine is a small molecule that 
is unable to induce antibodies directed against it.58 
 Immunotherapy is designed to chemically link nic-
otine to a carrier so that it acts as a hapten.59 This 
allows antibodies to bind to nicotine molecules in the 
plasma, resulting in a nicotine-antibody complex too 
large to cross the blood-brain barrier.60 Thus, anti-
nicotine antibodies change the kinetics of nicotine 
accumulation in the brain as well as the distribution 
of nicotine between the brain and other body  tissues. 
A review of four pharmaceutical trials found no 
long-term smoking cessation success to date,61 with 
none of these studies reporting any major side effects 
(NCT01178346, NCT001102114, NCT01280968).
Carson et al
98 Substance Abuse: Research and Treatment  2013:7
Alternative medical interventions  
and the role of pharmacogenomics
To date, alternative therapies such as acupuncture,62 
hypnotherapy,63 quit and win contests,64 and exercise 
interventions65 have, for the most part, been unsuc-
cessful as a smoking cessation aid. There is evidence 
to support the use of behavior modification and cogni-
tive interventions (including counseling and support 
programs), and these should be considered in com-
bination with all pharmacological interventions24,66 
and alternatives for people with contraindications to 
pharmacotherapies.50
Studies are currently underway to test genetic 
factors that may predict the effectiveness of 
 smoking  cessation therapies, including varenicline 
(NCT01228175) and nicotine replacement therapy 
(NCT00326781). Additionally, examinations into 
potential genetic moderators of nicotine, such as the 
mu opioid receptor gene (OPRM1) A118G polymor-
phism, are being investigated with the hypothesis 
that AG/GG genotype smokers will have attenuated 
subjective-rewarding from intravenous  administered 
nicotine compared to those with AA genotypes 
(NCT00969137). Specific nicotine biomarkers are 
also being evaluated to understand how these may 
influence a smoker’s decision to quit (NCT01314001). 
Using biological indicators as a motivator for smoking 
cessation is not a new concept, with spirometric ‘lung 
age’ used as a persuader in the early to mid-1980s.67 It 
is theorized that providing a smoker with an estimate 
of their individualized and personalized damage as a 
result of their tobacco use will motivate them into a 
quit attempt, though the exact mechanisms by which 
improvements are obtained remains unclear.68
Specific Populations
Young people
Some evidence-based guidelines recommend nico-
tine replacement therapy as a means of cessation for 
youth aged 12 to 18 years who are dependent on nico-
tine (ie, it is not recommended for use by occasional 
smokers).13 Other pharmacological interventions such 
as varenicline tartrate, however, have not yet specifi-
cally been evaluated for safety or efficacy in youth 
and should be considered with caution.  Considering 
that tobacco use typically begins in childhood or 
early adolescence69 with only 10% of new smokers 
initiating the habit after the age of 18 years,70 more 
investigation is needed in this area, particularly to 
prevent youth from experimenting with tobacco use 
in the first place.
Gender differences
Research suggests that gender differences exist in 
relation to nicotine dependence with females tending 
to smoke less and commence tobacco use at a later age 
than their male counterparts.71 Females are also less 
likely to be tobacco-dependent and subsequently less 
responsive to nicotine replacement therapy and more 
responsive to the sensory and behavioral aspects of 
smoking, which should be considered when consider-
ing smoking cessation initiatives.71 Moreover, clini-
cal research trials suggest that females may be more 
susceptible to the effects of tobacco use with greater 
deterioration of lung function, and more severe dis-
ease in subjects with chronic obstructive pulmonary 
disease.72
Hospitalized individuals, those awaiting 
surgery, and cancer patients
Each medical institution should have their own system 
for assisting individuals with craving control during 
times of enforced abstinence such as hospitalization, 
where smokers may not be able to access outdoor 
areas to smoke.13 This period of enforced abstinence 
also yields an opportunistic time to offer assistance 
to achieve long term abstinence. Varenicline tartrate 
has been trialed in hospitalized patients with tobac-
co-related illnesses, producing successful results at 
12 months follow-up.24 However, if craving control 
during hospitalization is the primary objective, then 
nicotine replacement therapy products offer the fastest 
delivery of nicotine to control cravings.13 Additional 
cessation support should be offered to patients with 
multi-session treatments and medications continu-
ing for at least one month post-discharge.13 Smoking 
cessation pharmacotherapies for cancer patients are 
also recommended to assist with craving control dur-
ing hospitalization or for obtaining long-term absti-
nence as described above. However, it is important to 
consider timing of quit attempts for these individuals 
due to physiological changes following cessation that 
may affect the metabolism of some drugs and target-
ing precision and accuracy of dose-volume histogram 
analyses for radiation therapy.73
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individuals with mental health issues
Pharmacotherapies for smoking cessation have been 
specifically evaluated in individuals with mental 
health issues. There are contraindications for some 
products such as varenicline tartrate and bupropion 
hydrochloride, which carry boxed warnings from the 
FDA for people with suicidal ideation, self-injurious 
behavior, and severe depression.74 People with mental 
health issues who stop smoking while taking medica-
tions for their illness should be monitored closely to 
determine if dosage reductions in their medications 
are necessary.13
Pregnant and breastfeeding women
It is well-known that smoking during pregnancy can 
have devastating health consequences not only on the 
mother, but also the unborn child including growth 
restriction, preterm delivery, and stillbirth.75–77 
 However, there are reports of up to 13% of women 
in the US78 and 18% in France79 continuing to smoke 
up until delivery, with higher prevalence estimates 
reported amongst indigenous women (45% during 
pregnancy increasing to 63% post-partum in one 
Australian population).80 Nicotine replacement thera-
pies can be considered for use by pregnant women; 
however, oral products are preferable to transdermal 
patches (for example gum, inhalers, micro tabs, and 
lozenges).13 Potential adverse effects are associated 
with all smoking cessation pharmacotherapies; thus, 
psychological interventions should be considered as 
the first line of treatment during pregnancy. There is a 
lack of evidence regarding safety for the use of other 
forms of pharmacological smoking cessation thera-
pies during pregnancy or while breastfeeding, though 
the risks of continued smoking must be weighed 
against the detrimental health consequences of con-
tinuing smoking.
indigenous populations
A 2012 Cochrane systematic analysis identified four 
studies evaluating pharmacological interventions 
for smoking cessation in indigenous populations 
globally. This review highlighted the paucity of data 
in this cohort, despite indigenous populations being 
over-represented in the burden of smoking related 
morbidity and mortality.81 The authors were able to 
conclude that there was some evidence of effective-
ness for combined pharmacological and cognitive 
initiatives that were culturally-tailored to the popu-
lation; however, the evidence base is not strong and 
highlights the need for methodologically rigorous tri-
als to bridge the gap between tobacco-related health 
disparities between the indigenous and non-indige-
nous populations. To date, FDA-approved nicotine 
transdermal patches and bupropion have been evalu-
ated in the indigenous setting, producing some suc-
cess in smoking abstinence, though studies are still 
needed to evaluate the safety and efficacy of vareni-
cline tartrate.
challenges to consider
Although many believe that the tobacco epidemic is 
under control, the latest epidemiological evaluations 
in developing countries suggest otherwise, with an 
increase in youth tobacco use, particularly amongst 
girls aged 13–15 years; aggressive tobacco industry 
marketing campaigns are mostly to blame.82 Moreover, 
the 2012 US Surgeon General’s Report states that rates 
of decline for tobacco smoking amongst youth have 
now stalled with smokeless tobacco use once again on 
the rise (Centers for Disease Control and Prevention 
and US Department of Health and Human Services, 
2012). For each person that dies because of a smoking 
related illness (more than 1,200 per day), at least two 
youths or young adults are becoming regular  smokers.2 
This increase in youth tobacco use today means an 
increase in adult daily tobacco users tomorrow. As 
an example, had the success that was made between 
1997 and 2003 been maintained in reducing youth 
tobacco use, there could potentially be three million 
fewer smokers in the United States of America today.2 
On a worldwide scale, tobacco use currently costs 
governments and consumers hundreds of billions of 
dollars each year in lost productivity and health care 
expenditures.4 Data on the global impact of tobacco 
is incomplete; however, it is known to be high, with 
annual tobacco-related health care costs US$81 billion 
in the US, US$7 billion in Germany, and US$1 bil-
lion in Australia.83 The cost in both human lives and 
economic resources will continue unless immediate 
action is taken to assist current tobacco users to quit, 
particularly those in high-risk populations, such as 
low- to medium-income countries, indigenous popu-
lations, and youth.
A major challenge for all tobacco researchers are 
smokers that are unwilling to quit. Most research to 
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date has focused on highly motivated individuals who 
are eager to attempt cessation. However, recalcitrant 
smokers who continue to smoke despite the known 
consequences pose the greatest problems, yet attract 
the least amount of attention. This may partly explain 
why smoking cessation pharmacotherapies that suc-
ceed within a randomized controlled trial fail to com-
pletely translate into the real world setting.15 Some 
research projects are underway to examine pharma-
cotherapeutic options for smokers unwilling to quit 
(NCT01195597); however, more research is needed. 
Similarly, insufficient research and clinical attention 
are given to maintaining abstinence once a person 
has made a quit attempt. Supporting long-term absti-
nence can be considered a costly endeavor over the 
short-term, requiring regular follow-up, prescription 
of ongoing pharmacological support, and alterations 
to existing cessation strategies that may require in-
depth consultations and discussions with the indi-
vidual regarding their quitting status. However, the 
long-term benefits such as improved health, reduced 
health care costs, lower governmental expenditure, 
and quality of life should outweigh the short-term 
output, but more research is needed in this area to 
encourage policy makers and governments to con-
sider such initiatives.84
Implications for Tobacco cessation  
in clinical practice and public policy
Although many people will quit tobacco use unaided, 
for some, particularly those with greater nicotine 
addiction, pharmacotherapies may offer the extra 
support needed to produce a successful long-term 
quit attempt. Many comprehensive, evidence-based 
clinical practice guidelines for smoking cessation 
have been developed. These are regularly updated 
by local governments and health institutions10,12–14,85 
and provide recommendations for clinical practice 
based on the latest available evidence. All of these 
guidelines recommend smoking cessation pharmaco-
therapies for smokers addicted to nicotine in addition 
to some form of regular counseling, as the chances 
of long-term abstinence are cumulative when used 
in combination.12 Efficacy data to date suggest that 
varenicline tartrate offers the best chance of long-term 
successful quit attempts,44,86 while nicotine replace-
ment therapy is ideally situated for short-term craving 
control and for individuals with contraindications to 
 varenicline or bupropion. Advice from health profes-
sionals trained in smoking cessation strategies have 
been shown to increase the number and success of quit 
attempts among their patients.87 Providing brief advice 
to most smokers (as little as 3 minutes) is more effec-
tive than spending longer time with a few patients.10 
Moreover, a Cochrane systematic review evaluating 
the training of health professionals in smoking cessa-
tion techniques found no evidence of additional ben-
efits for interventions of greater duration over brief 
interventions.87 It is important to remember that most 
patients will relapse multiple times before achiev-
ing successful long-term abstinence (known as the 
transtheoretical model of behavioral change theory), 
and guidelines for consultations are available to help 
individuals move from pre-contemplation to contem-
plation, preparation, action, and maintenance, which 
will eventually result in a successful quit attempt.88
Recalcitrant and continued smoking fails to be 
classified in many medical circles as an illness, with 
too many health professionals considering tobacco 
use as an individual’s right and freedom of expression 
foremost and as an illness second. Thus, implemen-
tation of tobacco cessation interventions is hindered. 
In reality, smokers become biologically dependent on 
nicotine, and until perceptions and attitudes within 
the health professions change, tobacco cessation pro-
grams will continue to be hampered.
Development of successful pharmacotherapies will 
do little if translation from research into public policy 
does not effectively occur. A multi-faceted approach 
is needed to increase the likelihood of success, which 
includes public policies such as smoking bans in pub-
lic places, restrictions on the purchase of tobacco 
products, increased governmental legislations, and 
mass media awareness campaigns. Increased taxa-
tion of tobacco products has been shown to prompt 
smoking cessation attempts and reduce existing pur-
chases of tobacco products, with research indicat-
ing that regular increases in tobacco tax may further 
encourage quitting activity.89 Governmental policies 
including tobacco product content regulation with 
extreme de-nicotinization and smoke pH regulation 
of cigarettes by tobacco companies have the potential 
to significantly impact tobacco use by reducing the 
addictive properties within cigarettes. Such legisla-
tion is necessary and overdue in many countries, as 
absorption of nicotine across biological  membranes 
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largely depends on pH.90 Thus, controlling the 
manufacture of cigarettes will reduce the addictive 
properties, allowing tobacco users to truly make an 
informed decision about wanting to smoke. As part 
of this multifaceted approach, smoking cessation 
training programs including motivational interview-
ing techniques for health professionals should be a 
mandatory component of medical training. Evidence 
confirms that a lack of training is a barrier to offering 
advice, as untrained health professionals report that 
they do not feel they have the skills, ability, or confi-
dence to implement tobacco cessation programs,91,92 
and yet the patients of health professionals trained 
in smoking cessation initiatives show statistically 
and clinically significant improvements in long-term 
abstinence.87
Future evaluations and Research 
(Gaps in current practice)
Nicotine addiction is a complex psychosocial, behav-
ioral, and biological process that is not well-under-
stood. For global reductions in tobacco use to occur, 
future researchers need to consider the biological and 
psychological aspects of nicotine addiction, as well 
as environmental factors contributing to existing lev-
els of tobacco use prevalence. Particularly, a key area 
lacking investigation concerns the transportation of 
smokers from pre-contemplation through to action. 
Research is needed to identify motivational triggers 
among these individuals and determine existing bar-
riers to smoking cessation. As technology advances, 
medical disciplines are moving toward the goal of 
personalized medicine, with individualized pharma-
cotherapies based on specific genetic and environ-
mental factors associated with each individual smoker, 
which may increase the number of quit attempts. 
 Researchers are consistently identifying new genetic 
properties that influence the pharmacokinetics and 
pharmacodynamics of nicotine, such as the poly-
morphism of the CYP2A6 isoenzyme, resulting in a 
developing field of research that requires attention. 
The inability of preliminary immunotherapy studies 
to produce efficacy in long-term smoking abstinence 
also requires investigation, with potential limitations 
of existing animal models under the spotlight.57
Research into gender variances are needed to 
understand the impact that biological and cognitive 
differences have in smoking cessation  strategies 
between the sexes,71 particularly with evidence sug-
gesting that females may be more susceptible to the 
lung-damaging effects of cigarette smoking than 
males.72 Additionally, the steady increase in female 
tobacco use and reduction in male tobacco use over 
recent decades needs to be considered in relation to 
observed gender differences in addiction and health 
effects resulting from tobacco use.93 Efficacy research 
examining existing pharmacotherapeutic aids for 
smoking cessation is also lacking in other specific 
populations such as youth, individuals with mental 
health issues, and indigenous populations.
There is a paucity of research to determine the 
efficacy of pharmacological interventions for smok-
ing cessation in the indigenous setting, while most 
indigenous populations are overrepresented in the 
burden of substance-related morbidity and mortality. 
Current evidence suggests that significant amounts 
of resources are being invested, particularly by 
government bodies, yet methodologically rigorous 
evaluation procedures are significantly lacking.81 
This carries substantial dangers with funding being 
invested into ineffective programs (which is possi-
ble without effective evaluations to determine true 
treatment efficacy), resulting in an opportunity cost 
for potentially effective initiatives.94 Moreover, the 
few previous studies report significant shortcomings 
relating to the effective implementation of research 
methodology as intended, particularly related to the 
uptake of pharmacotherapies and behavioral change 
interventions.81,94,95 This indicates that the next phase 
of tobacco-related research for the indigenous set-
ting should be qualitative in nature to examine where 
and why difficulties in existing research projects 
have occurred and to determine how they can be 
overcome.
Qualitative research has been underutilized in 
the tobacco arena mostly due to concerns regard-
ing methodological rigor and ambiguity in analyses 
resulting in qualitative analyses that lack strength.96 
However, because the nature of nicotine abuse is 
two-fold and includes physiological addiction to 
nicotine and behavioral components including habit, 
a mixed method approach (combination of qualita-
tive and quantitative research) should be consid-
ered. This will facilitate more thorough evaluation 
of areas where existing evidence is lacking, par-
ticularly for the specific populations as listed above 
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in which existing smoking cessation approaches 
 produce little effect.81,97–99 Such process evaluations, 
 particularly for key components such as context and 
fidelity, can provide essential information to interven-
tion studies across all settings.
conclusions
The most common pharmacological aids for smok-
ing cessation include nicotine replacement therapy, 
varenicline tartrate, and bupropion hydrochloride, 
with varenicline producing the greatest chance of 
long-term abstinence. Clinical practice guidelines 
recommend the use of counseling programs in con-
junction with pharmacological interventions, with 
regular follow-up and continued support to improve 
chances of success. Emerging pharmacotherapies 
include adaptations to existing treatments, evaluation 
of medications used to treat other conditions, and the 
use of genetic and biological factors that have the 
potential to influence the mechanisms of nicotine 
addiction. A primary objective of future research 
should be to develop initiatives, which may include 
high efficacy pharmacotherapies, to assist smokers 
who are not willing or report being unable to quit. 
Moreover, for smoking cessation pharmacotherapies 
to be successful, effective implementation strate-
gies must be clearly established with a multi-faceted 
approach that includes instigation of public policies, 
tobacco taxes, adequate support structures, and easy 
access to low-cost medications with high treatment 
efficacy.
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